Janus Henderson Group PLC Lowers Stock Holdings in Ocular Therapeutix, Inc. $OCUL

Janus Henderson Group PLC reduced its position in Ocular Therapeutix, Inc. (NASDAQ:OCUL) by 98.4% in the first quarter, Holdings Channel.com reports. The fund owned 68,500 shares of the biopharmaceutical company’s stock after selling 4,160,702 shares during the quarter. Janus Henderson Group PLC’s holdings in Ocular Therapeutix were worth $581,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of the company. Hilton Head Capital Partners LLC lifted its stake in Ocular Therapeutix by 30.4% in the 1st quarter. Hilton Head Capital Partners LLC now owns 4,520 shares of the biopharmaceutical company’s stock worth $38,000 after purchasing an additional 1,053 shares in the last quarter. Steward Partners Investment Advisory LLC increased its holdings in shares of Ocular Therapeutix by 124.2% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 2,242 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 1,242 shares during the period. The Manufacturers Life Insurance Company increased its holdings in shares of Ocular Therapeutix by 1.8% in the second quarter. The Manufacturers Life Insurance Company now owns 72,618 shares of the biopharmaceutical company’s stock worth $674,000 after purchasing an additional 1,314 shares during the period. Rafferty Asset Management LLC raised its position in shares of Ocular Therapeutix by 21.2% in the second quarter. Rafferty Asset Management LLC now owns 13,413 shares of the biopharmaceutical company’s stock worth $124,000 after buying an additional 2,343 shares in the last quarter. Finally, Rockefeller Capital Management L.P. bought a new stake in Ocular Therapeutix during the fourth quarter valued at $31,000. Hedge funds and other institutional investors own 59.21% of the company’s stock.

Analyst Upgrades and Downgrades

OCUL has been the subject of several recent analyst reports. Zacks Research cut Ocular Therapeutix from a “hold” rating to a “strong sell” rating in a research report on Tuesday, July 14th. Wall Street Zen upgraded Ocular Therapeutix from a “sell” rating to a “hold” rating in a research report on Saturday. HC Wainwright reissued a “buy” rating and set a $25.00 price objective (up from $21.00) on shares of Ocular Therapeutix in a report on Thursday, June 18th. Chardan Capital restated a “buy” rating and issued a $23.00 price objective on shares of Ocular Therapeutix in a research report on Tuesday, August 4th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Ocular Therapeutix in a research note on Friday, July 17th. Eleven equities research analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. According to MarketBeat, Ocular Therapeutix has an average rating of “Moderate Buy” and an average price target of $25.75.

Insider Activity at Ocular Therapeutix

In other news, insider Pravin Dugel sold 21,156 shares of the business’s stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $8.20, for a total value of $173,479.20. Following the completion of the sale, the insider owned 2,597,170 shares of the company’s stock, valued at approximately $21,296,794. The trade was a 0.81% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 28,999 shares of company stock valued at $237,792 in the last quarter. 3.10% of the stock is currently owned by insiders.

Ocular Therapeutix Trading Up 0.5%

OCUL stock opened at $9.24 on Tuesday. The company has a market capitalization of $2.03 billion, a PE ratio of -6.51 and a beta of 0.93. The company has a debt-to-equity ratio of 0.14, a quick ratio of 13.03 and a current ratio of 13.10. Ocular Therapeutix, Inc. has a one year low of $6.23 and a one year high of $16.44. The company’s 50 day moving average price is $9.16 and its two-hundred day moving average price is $9.08.

Ocular Therapeutix (NASDAQ:OCUL) last released its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.05. The company had revenue of $13.47 million for the quarter, compared to analyst estimates of $13.20 million. Ocular Therapeutix had a negative net margin of 579.10% and a negative return on equity of 59.89%. The firm’s quarterly revenue was down .1% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.39) EPS. As a group, analysts predict that Ocular Therapeutix, Inc. will post -1.5 earnings per share for the current fiscal year.

Ocular Therapeutix Profile

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.